First Patient in Pivotal Clinical Trial Treated with Algeness VL

This new clinical trial is being conducted through a partnership between Advanced Aesthetics Technologies and Lanzhou Biotechnique Development Co. and will be used to seek marketing approval in China.

AAT has commenced treatment of the first patient in China for a new pivotal trial of Algeness VL dermal filler.
AAT has commenced treatment of the first patient in China for a new pivotal trial of Algeness VL dermal filler.

Advanced Aesthetic Technologies, developer of Algeness VL (2.5% Agarose Gel) Filler, has initiated a clinical trial in China in partnership with Lanzhou Biotechnique Development Co. (LanDev) and their parent company China National Biotec Group Co. (CNBG). The study aims to evaluate the effectiveness and safety of Algeness VL in the treatment of moderate to severe nasolabial folds with commercially available hyaluronic acid fillers for injection as a control. 

"China's aesthetics market is growing faster than the global market. The size of the Chinese population and relatively low market penetration of aesthetics and filler treatments in China present enormous potential for future growth," said Doug Abel, CEO of AAT. "Our novel Algeness range of dermal fillers is the first 100% natural, biocompatible and fully biodegradable filler on the market to date, which differentiates it from other injectable products."

"We are proud to work with the AAT team to bring this revolutionary injectable product to the Chinese market. We believe the distinct advantages and high safety profile of the Algeness gel filler will resonate with aesthetic physicians and introduces a new category of biodegradable products to our growing portfolio," said Wu Qiang, general manager of LanDev.

Algeness holds a CE Mark and is currently distributed in more than 30 countries worldwide.

More in News